Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise ...

In its therapy, dubbed WVE-006, the company used a gRNA to lead ADAR enzymes to specific single-point mutations in the mRNA ...

Good afternoon, ladies and gentlemen, and welcome everyone to the Maravai Life Sciences third-quarter 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to ...

All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and ...

Maravai Lifesciences Holdings, Inc. ( (MRVI) ) has released its Q3 earnings. Here is a breakdown of the information Maravai Lifesciences ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Increasingly, injectables manufacturers recognise that to achieve maximum profitability, they need to focus on the value they ...

Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&DSAN DIEGO, Calif., ...

Carisma Therapeutics Inc.  ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming ...

The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...

Camp4 Therapeutics (CAMP) stock gains after J.P. Morgan and Piper Sandler launched its coverage with Overweight ...